The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ferring; Janssen; Lilly; MDS; Novartis
Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; Bayer; ESSA; Janssen-Cilag; Medivation; Millennium; Novartis; Ventana Medical Systems; Veridex
Speakers' Bureau - Astellas Pharma; Janssen; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Janssen; Janssen (I); Medivation; Ventana Medical Systems
Other Relationship - Institute of Cancer Research
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Bertrand F. Tombal
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Janssen
Research Funding - Ferring (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Maha Hussain
Honoraria - Onclive; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi
 
Cora N. Sternberg
No Relationships to Disclose
 
De Phung
Employment - Astellas Pharma
 
Shevani Naidoo
Employment - Astellas Pharma
 
Katharina Modelska
Employment - Pfizer
 
Arlene Reisman
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Cristina Ivanescu
Employment - Idenix
Consulting or Advisory Role - Astellas Pharma
 
David F. Penson
Consulting or Advisory Role - Astellas Pharma; Dendreon; Janssen
Research Funding - Astellas Pharma (Inst)